The European Banking Authority (EBA) has classified USDC as a significant e-money token under the EU's MiCA regulation, effective from November 12, 2026. This means the EBA will directly supervise the issuer's financial safeguards, including reserves and liquidity, taking over some responsibilities from France's ACPR. However, this change affects only the issuer's regulation, not the casinos or payment providers accepting USDC, which remain under separate national gambling and crypto-payment rules. The new status may lead to stricter compliance expectations for stablecoins but does not alter how USDC transactions are handled at online casinos.
USDC's new classification as a significant e-money token in Europe provides context for crypto market activity. For readers following the broader cryptocurrency market, here is Pluang's snapshot as of Nov 09, 2026 16:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable movers include ALGO at Rp1.637 with a 1-day change of -4.94% and a Pluang order activity split of 73% Sell / 27% Buy, SNX at Rp2.831 down 4.68% with 34% Sell / 66% Buy, and UNI at Rp122.135 down 4.57% with 93% Sell / 7% Buy.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
